Article

The Desmin Mutation DES-c.735G>C Causes Severe Restrictive Cardiomyopathy by Inducing In-Frame Skipping of Exon-3

Andreas Brodehl 1,*, Carsten Hain 2, Franziska Flottmann 1, Sandra Ratnavadivel 1 ©, Anna Gaertner 1 ©, Bärbel Klauke 1,3, Jörn Kalinowski 2, Hermann Körperich 4 ©, Jan Gummert 1,5, Lech Paluszkiewicz 5 ©, Marcus-André Deutsch 5 and Hendrik Milting 1, * ©

1 Heart and Diabetes Center NRW, Erich and Hanna Klessmann Institute, University Hospital of the Ruhr-University Bochum, Georgstrasse 11, D-32545 Bad Oeynhausen, Germany; franziska.flottmann@uni-bielefeld.de (F.F.); sratnavadivel@hdz-nrw.de (S.R.); aagaertner@hdz-nrw.de (A.G.); bklauke@hdz-nrw.de (B.K.); jgummert@hdz-nrw.de (J.G.)
2 Microbial Genomics and Biotechnology, Center for Biotechnology, Bielefeld University, D-33615 Bielefeld, Germany; chain@cebitec.uni-bielefeld.de (C.H.); joern@CeBiTec.Uni-Bielefeld.de (J.K.)
3 Clinic for General and Interventional Cardiology/ Angiology, Heart and Diabetes Center NRW, University Hospital of the Ruhr-University Bochum, Georgstrasse 11, D-32545 Bad Oeynhausen, Germany
4 Heart and Diabetes Center NRW, Institute for Radiology, Nuclear Medicine and Molecular Imaging, University Hospital of the Ruhr-University Bochum, Georgstrasse 11, D-32545 Bad Oeynhausen, Germany; hkoerperich@hdz-nrw.de
5 Heart and Diabetes Center NRW, Department of Thoracic and Cardiovascular Surgery, University Hospital Ruhr-University Bochum, Georgstrasse 11, D-32545 Bad Oeynhausen, Germany; lpaluszkieiyouz@hdz-nrw.de (I.P.); mdeutsch@hdz-nrw.de (M.-A.D.)
* Correspondence: abrodehl@hdz-nrw.de (A.B.); hmliting@hdz-nrw.de (H.M.); Tel.: +49-(0)5731-973510 (A.B.); +49-(0)5731-973510 (H.M.)

Abstract: Currently, little is known about the genetic background of restrictive cardiomyopathy (RCM). Herein, we screened an index patient with RCM in combination with atrial fibrillation using a next generation sequencing (NGS) approach and identified the heterozygous mutation DES-c.735G>C. As DES-c.735G>C affects the last base pair of exon-3, it is unknown whether putative missense or splice site mutations are caused. Therefore, we applied nanopore amplicon sequencing revealing the expression of a transcript without exon-3 in the explanted myocardial tissue of the index patient. Western blot analysis verified this finding at the protein level. In addition, we performed cell culture experiments revealing an abnormal cytoplasmic aggregation of the truncated desmin protein. Mutations in DES cause different cardiac and skeletal myopathies [1,2] or combinations of both [3]. Although the exact incidence of pathogenic DES mutations is unknown, desminopathy is a rare disease with an estimated incidence of less than 1 in 2000 [4]. Desmin consists of an α-helical rod domain flanked by non-helical head and tail domains. It forms coiled-coil dimers, which anneal antiparallel into tetramers [5]. Eight antiparallel tetramers form unit-length filaments (ULFs), which are the essential building blocks of intermediate filaments [4]. Desmin filaments connect different cell organelles and multi-protein complexes, like the cardiac desmosomes, costameres, and Z-bands, and are, therefore, highly relevant for the cardiac desmosomes, costameres, and Z-bands, and are, therefore, highly relevant for...
the structural integrity of cardiomyocytes [6]. The majority of known pathogenic DES mutations are missense mutations or small in-frame deletions that potentially change the physical properties of desmin [4,7,8]. Since prolines destabilize α-helices, many pathogenic DES missense mutations leading to an exchange against proline have been described [9]. DES mutations interfere at different stages within the filament assembly process leading to an abnormal cytoplasmic desmin aggregation [10]. Heterozygous splice site mutations or other loss of function mutations in the DES gene are rare [11,12].

Herein, we describe an index patient with a heterozygous in-frame exon skipping desminopathy who developed severe restrictive cardiomyopathy (RCM) in combination with atrial fibrillation and, finally, underwent heart transplantation (HTx). The majority of RCM associated mutations have been described in genes encoding sarcomeric proteins, like cardiac troponins or filamin-C [13–17]. Since several different genes are associated with RCM, we performed NGS analysis revealing the heterozygous DES-c.735G>C mutation, which is most likely disease causing within the described family. Several other family members were affected by skeletal or cardiac myopathies. DES-c.735G>C might cause the exchange of glutamate against aspartate at position 245 (p.E245D).

However, the mutant nucleotide is the last one of exon-3. Previously, Clemen et al. demonstrated in skeletal muscle tissue that in addition to the missense exchange (p.E245D) an exon skipping is induced by this mutation [18]. This exon skipping leads to an in-frame deletion of 96 base pairs (32 amino acids). However, the ratio of the missense and the deletion mutations in the human heart remains unknown. Therefore, we investigated by nanopore sequencing the myocardial expression levels of mutant and wild-type DES transcripts. Of note, these experiments revealed skipping of the DES exon-3 but excluded p.E245D transcripts.

Additionally, we generated expression constructs of the missense mutation and of the in-frame deletion (p.D214-E245del) resulting from exon-3 skipping and analysed the filament assembly in cell culture in combination with confocal microscopy revealing an abnormal cytoplasmic aggregation of the in-frame exon deletion but not of the missense mutation as previously described for several other DES mutations [19–21]. Immunohistochemistry (IHC) confirmed likewise desmin aggregates and degraded sarcomeres in the explanted myocardial tissue of the index patient.

In conclusion, we demonstrated by nanopore sequencing that an in-frame exon skipping is caused by DES-c.735G>C leading to a filament assembly defect of the mutant desmin, which is likely causative for RCM.

2. Materials and Methods
2.1. Clinical Description of the Index Patient (III-9)

The index patient presented decompensated right heart failure at the age of 41 years and was admitted with edema of the legs, hepatomegaly, shortness of breath (NYHA III), nycturia, and palpitations. Electrocardiogram (ECG) analyses revealed atrial fibrillation. Transthoracic echocardiography (TTE) analyses revealed moderate to severe tricuspid valve regurgitation and massive dilation of the right atrium (RA) with associated spontaneous echo contrast. Slight dilation of the right ventricle (RV) but excluded left-ventricular (LV) dilation (Figure 1A,B).
biopsies revealed an increased number (>7 cells/mm²) of activated T-cells (CD45R0) and macrophages (CD68) indicating myocardial inflammation (Figure F,G) [22]. Due to progressive clinical worsening (Ergospirometry: VO₂max 9.81 mL/kgKG/min; right-heart catheterization (20 h after levosimendan therapy): PCWP 15 mmHg, CI 1.4 l/min/m²), the patient was listed for highly urgent HTx). He finally underwent orthotopic HTx at the age of 43. In total, the clinical presentation of III-9 is in good agreement with the diagnosis of RCM.

Figure 1. Clinical findings in index patient III-9 with RCM and persistent atrial fibrillation. (A) 2D transthoracic echocardiography. Apical four chamber view. Note enlargement of both atria with relatively small ventricles. A small amount of pericardial effusion is also visible. (B) Transthoracic echocardiography. Apical four chamber view, PW-Doppler of the mitral valve inflow. (C–E) Cardiac magnetic resonance imaging of III-9. (C,D) End-diastolic cine steady-state free-precession acquisitions. (E) Early 3D inversion-recovery T1-weighted fast gradient-echo for thrombus detection. (RA = right atrium; LA = left atrium; RV = right ventricle; and LV = left ventricle. A wall-adherent thrombus in the RA (34 × 25 × 17 mm) is marked with a white arrow head. Pericardial effusion (orange arrow head) was present, and pleural effusion (asterisk) was detected. (F,G) Immunohistology analysis of a right ventricular biopsy revealed myocardial inflammation. (200× magnification) (F) CD68 staining revealed increased number of macrophages. (G) CD45R0 staining revealed increased number of activated T-cells.

While systolic left-ventricular ejection fraction (LVEF) was preserved mitral inflow signal analysis revealed severe diastolic dysfunction. In addition, a wall-adherent thrombus in the RA was diagnosed. Cardiac magnetic resonance imaging (MRI) verified intense dilation of the RA (end-diastolic area about 60 cm²) and moderate dilation of the LA (end-diastolic area 34 cm²) (Figure 1C–E and Supplementary Material Video S1).
The LV diameters were normal (LV-EDD 39 mm and LV-ESD 26 mm) and the RV diameters were slightly increased (RV-EDD 35 mm and RV-ESD 22 mm). RV myocardial biopsies revealed an increased number (>7 cells/mm²) of activated T-cells (CD45R0) and macrophages (CD68) indicating myocardial inflammation (Figure 1F,G) [22]. Due to progressive clinical worsening (Ergospirometry: VO₂max 9.81 mL/kg kg/min; right-heart catheterization (20 h after levosimendan therapy): PCWP 15 mmHg, CI 1.4 L/min/m²), the patient was listed for highly urgent HTx. He finally underwent orthotopic HTx at the age of 43. In total, the clinical presentation of III-9 is in good agreement with the diagnosis of RCM.

2.2. Genetic Analyses

The family anamnesis of the index patient (III-9, Figure 2) revealed five further family members with skeletal and/or cardiac myopathies. His father (II-5) was deceased by an unclassified cardiomyopathy, and two uncles (II-1 and II-3) and a cousin (III-5) developed skeletal myopathy. Of note, II-1 additionally developed cardiomyopathy and underwent HTx. Furthermore, the grandmother (I-2) developed an unspecified cardiomyopathy. Detailed clinical data of the affected family members were not available.

After identification of significant family history of skeletal and cardiac myopathies, we applied the TrueSight Cardio NGS panel (Illumina, San Diego, CA, USA) covering the most likely cardiomyopathy associated genes (see the Appendix A for a complete gene list) to investigate the putative underlying mutations in the index patient (III-9). The MiSeq system (Illumina) was used for NGS. No genomic DNA was available from further family members to perform co-segregation analysis within the family. A minor allele frequency (MAF) < 0.001 was used for filtering of identified sequence variants. Sanger sequencing was used to verify DES–c.735G>C using appropriate primers (Table 1).

Figure 2. Pedigree of the described family. Circles represent females, squares represent males, and rhombs represent unknown gender. Black-filled symbols indicate a cardiac or skeletal muscle phenotype. Diagonal slashes indicate deceased people. The index patient (III-9) is marked with an arrow and carries DES-c.735G>C. CM = Cardiomyopathy; HTx = Heart transplantation; SM = Skeletal myopathy; and RCM = Restrictive cardiomyopathy.
Table 1. Overview of the used oligonucleotides 1.

| Name          | Sequence (5′-3′)                   | Application          |
|---------------|-----------------------------------|----------------------|
| DES_3F        | GGAAGAAGCAGAGAACAATTTGGC          | Sanger sequencing    |
| DES_3R        | ACCTGGACCTGCTGTTCCCTG             | Sanger sequencing    |
| oligo(dT)18   | TTTTTTTTTTTTTTTTTTT             | Reverse transcription |
| DES_for       | ATGACGCCAGCCCCCTACTCGTC          | RT-PCR               |
| DES_rev       | GAGCACTTCATGCTGCTGTC             | RT-PCR               |
| DES_E245D_for| TAAGAAAGTGCATGAAGACGAGATCCGTGAGTTGAG | SDM                  |
| DES_E245D_rev| CTGCAACTCAGGGATCTCGTCTCATGCACTTCTTA | SDM                  |
| DES_E3_Del_for| GCTGCTTCCGAGCGGAGATCCGTGAGTTG     | SDM                  |
| DES_E3_Del_rev| CAACTCACGGATCTCCCGTCGGGAAGGCGAC  | SDM                  |

1 All oligonucleotides were purchased from Microsynth (Balgach, Switzerland). RT-PCR = reverse transcription polymerase chain reaction, and SDM = site directed mutagenesis.

2.3. Reverse Transcription Polymerase Chain Reaction

The total RNA was extracted from about 30 mg myocardial tissue from the index patient (III-9) and a rejected donor heart (non-failing, NF) according to the manufacturer’s instructions. We transcribed 1.2 µg total RNA into cDNA using SuperScript II reverse transcriptase (Thermo Fisher Scientific, Waltham, MA, USA) in combination with oligo(dT)18 primers (Table 1) according to the manufacturer’s instructions. Reverse transcription polymerase chain reaction (RT-PCR) was performed using the appropriate primers (Table 1, 1 µM), Phusion DNA polymerase, and HF buffer (Thermo Fisher Scientific). The annealing temperature was 60 °C, and 35 cycles were used for PCR amplification. The full-length PCR products were purified with the GeneJET Gel Extraction Kit (Thermo Fisher Scientific) and were processed to nanopore sequencing.

2.4. Amplicon Nanopore Sequencing

DES cDNA was sequenced using the SQK-LSK109 kit on a GridION with 9.4.1. flow-cells (Oxford Nanopore Technologies, Cambridge, UK). Base calling was carried out with guppy v5.0.11 and the super-accurate base call model. Fastq data was adapter trimmed using porechop v0.2.4 (https://github.com/rrwick/Porechop, accessed on 28 July 2021) and mapped on the human reference genome hg38 using minimap2 v2.10-r761 with the -x splice parameter [23].

Alignment sorting and bam conversion was carried out using samtools v1.11. Isoform analysis was carried out using FLAIR v1.5.1. with the align, correct, collapse, and quantify steps [24]. Isoforms with less than 1% of reads supported were discarded.

2.5. Immunohistochemistry

Explanted septal, left-, and right–ventricular myocardial tissue was fixed in 4% Roti Histofix (Carl Roth, Karlsruhe, Germany) and was embedded in paraffin. We prepared 5 µm sections using a microtome (Leica, Wetzlar, Germany) that were deparaffinized using xylene and ethanol as described [25]. Bovine serum albumin (5% in phosphate buffered saline, PBS) was used for blocking (30 min, room temperature). Polyclonal goat anti-desmin antibodies (15 µg/mL, #AF3844, R&D Systems, Minneapolis, MN, USA) were used in combination with secondary anti-goat antibodies conjugated to Cy3 (1:100, #C2821, Sigma-Aldrich, St. Louis, MO, USA) for desmin labelling. We used 4′,6-diamidino-2-phenylindole (DAPI, 1 µg/mL) for nuclei staining (5 min, RT). Myocardial tissue was embedded using Fluorescent Mounting Medium (Dako, Glostrup, Denmark). Confocal microscopy was performed as previously described [26].
2.6. Plasmid Generation

The plasmid pEYFP-N1-DES was previously described [27]. The QuikChange Lightning Site-Directed Mutagenesis (SDM) Kit was used according to the manufacturer’s instruction to insert the missense variant DES-p.E245D and the deletion DES-p.D214-E245del into this plasmid using appropriate oligonucleotides (Table 1). The DES encoding sequences of all three plasmids were verified using Sanger sequencing (Macrogen, Amsterdam, The Netherlands). For details, see the Figure S1 in the Supplementary Materials.

2.7. Cell Culture and Confocal Microscopy

The cell line SW13 does not express any cytoplasmic IF proteins and is, therefore, frequently used to investigate the effects of DES mutations [28]. SW13 cells were cultivated in Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with 10% fetal calf serum and penicilline/streptomycine under standard conditions (37 °C, 5% CO₂). Cells were cultured in µslide chambers (ibidi, Martinsried, Germany) and were transfected using Lipofectamin 3000 according to the manufacturer’s instruction (Thermo Fisher Scientific). After 24 h of transfection, the cells were washed with PBS and fixed for 10 min with 4% Roti Histofix (Carl Roth, Karlsruhe, Germany) at RT.

Afterwards, the cells were washed gently with PBS and were incubated with 0.1% Triton-X-100 for 15 min at RT. Phalloidin conjugated with Texas-Red-X (1:40, # T7471, Thermo Fisher Scientific) and DAPI (1 µg/mL) were used for the costaining of F-actin and the nuclei. Confocal microscopy was performed as described [29]. Approximately 100 cells were analyzed in each transfection experiment (n = 4).

2.8. Western Blot Analysis

About 50 mg left-ventricular myocardial tissue from a control sample (NF) and the index patient III-9 were homogenized and lysed in RIPA lysis buffer [30] supplemented with proteinase inhibitors. Protein concentrations were determined using the Pierce 660 nm Protein Assay (Thermo Fisher Scientific) in combination with the Infinite M1000 plate reader (Tecan, Männedorf, Switzerland). Western blot analysis was performed using chemiluminescence measurement as previously described [27].

2.9. Statistical Analysis

About 100 cells per independent transfection experiment (n = 4) were analyzed by counting the percentage of aggregate forming cells. A non-parametric Mann–Whitney test was used for analysis using GraphPad Prism 8.3 (GraphPad Software, San Diego, CA, USA). p-values ≤ 0.05 were considered as significant.

3. Results

The index patient (III-9, Figure 2) developed severe RCM and received HTx at the age of 43. Family anamnesis revealed five further family members (I-2, II-1, II-3, II-5, and III-5, Figure 1) affected by cardiomyopathy and/or skeletal myopathy indicating an autosomal-dominant mode of inheritance.

We performed a genetic analysis using a broad NGS gene panel revealing heterozygous DES-c.735G>C as the most likely pathogenic variant. The MAFs of all other identified variants were higher than the estimated prevalence of RCM. Interestingly, DES-c.735G>C changes the last base pair of DES exon-3 (Figure 3A). Sanger sequencing confirmed the presence of this DES mutation (Figure 3B).
Figure 3. Genetic analysis of the index patient (III-9). (A) Integrated genome view of DES exon-3 revealed DES-c.735G>C in the gDNA from III-9 (red arrow). Cytosine was detected in 291 reads (53%, 131+, 160−), and guanosine was detected in 258 reads (47%, 119+, 139−). Reads are shown in grey. (B) Electropherogram of DES-c.735G>C generated by Sanger sequencing using gDNA from III-9 (red arrow). Of note, this missense mutation changes the last nucleotide in exon-3. Since the affected last base pair of exon-3 is part of a relatively conserved splice site, it is possible that this mutation causes a splicing defect (p.D214-E245del) and/or an amino acid exchange (p.E245D). To address this issue, we used RT-PCR in combination with nanopore sequencing to identify the myocardial DES transcripts in the index patient. In addition to the wild-type form, additional transcripts without the DES exon-3 were found in the patient sample but not in the non-failing control sample (Figure 4). Notably, we were unable to detect significant transcripts leading to the amino acid exchange p.E245D indicating that exon-3 skipping is the underlying pathomechanism.

To verify the results of the nanopore sequencing at the protein level, we performed western blotting (Figure 5). The skipping of exon-3 causes an in-frame deletion leading to a truncated protein (p.D214-E245del). Accordingly, we detected, in addition to the wild-type desmin (~55 kDa), a second smaller band (~50 kDa) using left-ventricular myocardial tissue from the index patient III-9 but not in case of the control sample (Figure 5).
Figure 4. (A) Schematic overview of the DES gene. Arrow heads indicate the localization of the oligonucleotides used for amplification. Exons 1–9 are shown as blue boxes. Amplicon analysis of a control sample (B) and of the index patient III-9 (C). In addition to the regular transcript (NM_001927.4), a transcript missing exon-3 was found in III-9 (red arrow) but not in the control sample. Of note, transcripts encoding the missense variant p.E245D were absent in both samples indicating that DES-c.735G>C causes an in-frame exon skipping but not a missense variant in the myocardial tissue from the index patient III-9 (A:44; C:44; G:7523; T:8).

Figure 5. Western blotting analysis using myocardial tissue from a control sample (NF) and the index patient III-9. Of note, in the case of the index patient, two bands were observed, which correspond to wild-type desmin (black arrow head) and desmin-p.D214-E245del (red arrow head).

In the next step, we introduced p.E245D and p.D214-E245del into expression plasmids (Supplementary Materials) and performed transfection experiments in SW13 cells, which do not express any cytoplasmic intermediate filament proteins. Analyses using confocal microscopy revealed for wild-type and p.E245D intermediate filaments, whereas the expression of desmin-p.D214-E245del induced an abnormal cytoplasmic aggregation indicating a severe filament assembly defect (Figure 6A). Quantification revealed that all cells expressing mutant desmin-p.D214-E245del were positive for these cytoplasmic aggregates (Figure 6B).
Figure 6. (A) Fluorescence analysis of transfected SW13 cells. Of note, desmin-p.D214-E245del causes severe desmin aggregation (white arrows), whereas wild-type and desmin-p.E245D form intermediate filaments (green arrows). Desmin is expressed as a fusion protein with EYFP (shown in green). F-actin is stained using phalloidin conjugated with Texas-Red (red) and nuclei are stained using DAPI (shown in blue). Scale bars represent 10 µm. (B) Quantification of desmin aggregate formation in transfected cells. About 100 cells have been analyzed per transfection experiment (n = 4). Error bars represent SD. Non-parametric Mann–Whitney-U-test was used for statistical analysis. n.s. = not significant; * indicate p-values < 0.05.

In addition, we performed IHC analyses using explanted tissue from all three myocardial layers revealing sarcomeric structures with irregular desmin signals as well as desmin positive aggregates in the heart of the index patient (III-9). Notably, desmin staining at the intercalated disc was not observed in the myocardial tissue from III-9 (Figure 7).

Figure 7. Immunohistochemistry analysis of explanted myocardial tissue from the index patient III-9. LV = left ventricular myocardial tissue; RV = right ventricular myocardial tissue; and S = septal myocardial tissue. Scale bars represent 50 µm. Desmin is shown in red. Nuclei were stained using DAPI and are shown in blue. Of note, desmin-positive aggregates were present in all three layers (white arrows). In addition, desmin-negative areas were present (yellow arrows) representing fibroblast or other non-cardiomyocyte cell types.
4. Discussion

DES mutations cause a broad spectrum of myopathies and different cardiomyopathies [31], including RCM [1,32–34]. Most of these DES mutations cause single amino acid exchanges, which interfere with desmin filament assembly at different molecular stages [10,28]. In this study, using an NGS approach, we identified the desmin mutation DES-c.735G>C in an index patient from a family, in which several members developed skeletal myopathies or cardiomyopathies.

Since we do not have gDNA from further family members, we were unable to perform a co-segregation analysis of DES-c.735G>C in the family. However, DES-c.735G>C is absent in the Genome Aggregation Database (gnomAD, https://gnomad.broadinstitute.org/, 6 August 2021) and in the NHLBI GO Exome Sequencing Project (https://evs.gs.washington.edu/, 6 August 2021). According to the guidelines of the American College of Medical Genetics and Genomics (ACMG) absence from controls is a moderate criterion for pathogenicity (PM2, ACMG guidelines) [35].

Notably, this mutation has been previously classified as a pathogenic variant found in patients with RCM in combination with atrial fibrillation [36], patients with distal myopathy in combination with cardiac conduction disease [18,37], or in patients with hypertrophic cardiomyopathy (HCM) in combination with cardiac conduction disease [38]. Classifying genetic mutations as 'pathogenic' in the literature without independent evaluation is a supportive criterion (PP5, ACMG guidelines). DES-c.735G>C is changing the last base pair of exon-3. Therefore, a damaging effect arising from a putative missense mutation (p.E245D) or a splice defect might be causative.

Previously, Clemen et al. performed RT-PCR in combination with cloning and Sanger sequencing and revealed the expression of both mutant forms (p.E245D and p.D214-E245del) in the skeletal muscle of their patients [18]. However, whether the DES-c.735G>C mutation also leads to the expression of both mutant desmin species in the myocardial tissue is unknown. Therefore, we performed full length RT-PCR in combination with nanopore amplicon sequencing. As expected due to the heterozygous status of the index patient III-9, these experiments revealed the expression of the wild-type form as well as of DES-r.640-735del. However, transcripts encoding for DES-p.E245D have not been found in significant quantity. These experiments indicate that the truncated desmin caused by skipping of exon-3 is the pathogenic desmin species in the myocardial tissue. To verify these findings, we performed western blotting corroborating the expression of desmin-p.D214-E245del at the protein level. Changes in the protein length due to in-frame deletions are a moderate criterion for pathogenicity (PM4, ACMG guidelines) [35].

Most of the pathogenic DES mutations cause an abnormal cytoplasmic desmin aggregation [27,39]. Therefore, we inserted DES-p.D214-E245del and DES-p.E245D into expression plasmids and analyzed the filament assembly in transfected SW13 cells. These experiments revealed an abnormal cytoplasmic desmin aggregation of the truncated form but not of the missense mutation p.E245D when compared to wild-type desmin. Previously, Bär et al. showed that desmin-p.E245D forms regular intermediate filaments in transfected SW13 cells and does not interfere significantly with filament assembly using recombinant mutant desmin [10].

According to our cell culture experiments, we have found typical desmin-positive aggregates also in the explanted myocardial tissue of III-9. In general, functional studies are a strong criterion (PS3, ACMG guidelines) for pathogenicity according to the ACMG guidelines [35]. Therefore, DES-c.735G>C fulfills this criterion, as we have shown that the truncated desmin-p.D214-E245del causes an abnormal cytoplasmic aggregation as previously described for several other pathogenic DES mutations. In addition, this mutation is localized in the rod domain of desmin, which is a hot spot for pathogenic DES mutations [31], which is a moderate criterion (PM1, ACMG guidelines) for pathogenicity. Interestingly, several other pathogenic mutations affecting the donor splice-site of DES exon-3 have been previously described [40–43].
In summary, we have shown here that DES-c.735G>C causes a splicing defect in cardiac muscle leading to skipping of exon-3 and the expression of truncated desmin-p.D214-E245del, which is unable to form regular intermediate filaments in transfected cells. DES-c.735G>C fulfills one strong (PS3), one supportive (PP5), and three moderate criteria (PM1, PM2, and PM4) for its pathogenicity classification. In consequence, DES-c.735G>C has to be classified according to the ACMG guidelines as a pathogenic mutation associated with RCM.

5. Conclusions

By using an NGS approach, we identified the pathogenic DES-c.735G>C mutation in a patient with RCM. Using nanopore sequencing, we demonstrated that DES-c.735G>C causes a skipping of the third DES exon. Genetic and molecular analyses support pathogenicity of the caused splice site defect rather than a putative missense mutation p.E245D. In the future, our genetic and functional findings might be helpful for the genetic understanding of similar cases.

Supplementary Materials: The following are available online at https://www.mdpi.com/article/10.3390/biomedicines9101400/s1, Figure S1: Plasmid maps of pEYFP-N1-DES-WT/-p.E245D and pEYFP-N1-DES-p.D214-E245del. Video S1: MRI video file.

Author Contributions: Conceptualization, A.B.; formal analysis, A.B., C.H., F.F. and S.R.; experimental investigations, A.B., C.H., F.F. and S.R.; clinical investigations H.K., J.G., L.P. and M.-A.D.; resources, J.K.; data curation, A.B., C.H., F.F., A.G., B.K., H.K., L.P. and M.-A.D.; writing—original draft preparation, A.B.; writing—review and editing, C.H., F.F., S.R., A.G., B.K., J.K., H.K., J.G., L.P., M.-A.D. and H.M.; visualization, A.B., C.H., F.F. and S.R.; supervision, A.B.; project administration, A.B.; funding acquisition, A.B. and H.M. All authors have read and agreed to the published version of the manuscript.

Funding: This research project was supported by the Ruhr-University Bochum, FoRUM, F937R2 (A.B. and H.M.).

Institutional Review Board Statement: The study was conducted according to the guidelines of the Declaration of Helsinki and was approved by the ethics committee of the Ruhr-University Bochum (Bad Oeynhausen, Reg.-No. 2018-330, 1 March 2018).

Informed Consent Statement: Written informed consent has been obtained from the patient(s) involved in this study.

Data Availability Statement: The data used and/or analyzed during the current study are available from the corresponding authors on reasonable request.

Acknowledgments: We thank all contributing patients for the continuous support of our research. In addition, we would like to thank Caroline Stanasiuk for technical assistance and Martin Farr for proofreading. We are also thankful to Rolf Schröder and Christoph Clemen for constructive discussions and helpful suggestions.

Conflicts of Interest: The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

Appendix A

Overview about the used NGS gene panel: ABCC9, ABCG5, ABCG8, ACTA1, ACTA2, ACTC1, ACTN2, AKAP9, ALMS1, ANK2, ANKR1D1, APOA4, APOA5, APOB, APOC1, APOE, BAG3, BRAF, CACNA1C, CACNA2D1, CACNB2, CALM1, CALR3, CASQ2, CAV3, CBL, CB5, CETP, COL3A1, COL5A1, COL5A2, COX15, CREB3L1, CRELD1, CRYAB, CSRP3, CT1, DCS, DMD, DNAJC19, DOLK, DPP6, DSC2, DSG2, DSP, DTNA, EFEMP2, ELN, EMD, EYA4, FBN1, FBN2, FHL1, FHL2, FKRP, FKTN, FXN, GAA, GATAD1, GCKR, GJA5, GLA, GPD1L, GPIHBP1, HADHA, HCN4, HFE, HRS, HSPB8, ILK, JAG1, JPH2, JUP, KCNA5, KCND3, KCNE1, KCNE2, KCNE3, KCN2, KONJ2, KONJ5, KONJ8, KONQ1, KLF10, KRAS, LAMA2, LAMA4, LAMP2, LDB3, LDLR, LDLRAP1, LMFI, LMNA, LPL,
LTBP2, MAP2K1, MAP2K2, MIB1, MURC, MYBPC3, MYH11, MYH6, MYH7, MYL2, MYL3, MLK, MYLK2, MYO6, MYOZ2, MYPTN, NEXN, NXX2-5, NODAL, NOTCH1, NPPA, NRAS, PCSK9, PDLIM3, PKP2, PLN, PRDM16, PRKAG2, PRKAR1A, PTPN11, RAF1, RANGRF, RBM20, RYR1, RYR2, SALL4, SCN1B, SCN2B, SCN3B, SCN4B, SCN5A, SCOC2, SDHA, SEPN1, SGCB, SGCD, SGCG, SHOC2, SLC25A4, SLC2A10, SMAD3, SMAD4, SNTA1, SOS1, SREBF2, TAZ, TXB20, TXB3, TBX5, TCAF, TGFBR2, TGFBR3, TGFBR1, TMEM43, TMP0, TNCCN1, TNN3, TNNT2, TPM1, TRDN, TRIM63, TRPM4, TTN, TTR, TXNRD2, VCL, ZBTB17, ZHX3, ZIC3.

References

1. Brodehl, A.; Pour Hakimi, S.A.; Stanasiuk, C.; Ratnavadivel, S.; Hendig, D.; Gaertner, A.; Gerull, B.; Gummert, J.; Paluszkiewicz, L.; Milting, H. Restrictive Cardiomyopathy is Caused by a Novel Homozygous Desmin (DES) Mutation p.Y122H Leading to a Severe Filament Assembly Defect. Genes 2019, 10, 918. [CrossRef] [PubMed]

2. Brodehl, A.; Dieding, M.; Biere, N.; Unger, A.; Klauke, B.; Walhorn, V.; Gummert, J.; Schulz, U.; Linke, W.A.; Gerull, B.; et al. Functional characterization of the novel DES mutation p.136F associated with dilated cardiomyopathy reveals a dominant filament assembly defect. J. Mol. Cell. Cardiol. 2016, 91, 207–214. [CrossRef] [PubMed]

3. Schirmer, I.; Dieding, M.; Klaue, B.; Brodehl, A.; Gaertner-Rommel, A.; Walhorn, V.; Gummert, J.; Schulz, U.; Paluszkiewicz, L.; Anselmetti, D.; et al. A novel desmin (DES) indel mutation causes severe atypical cardiomyopathy in combination with atriointerventricular block and skeletal myopathy. Mol. Genet. Genom. Med. 2018, 6, 288–293. [CrossRef]

4. Clemen, C.S.; Herrmann, H.; Strelkov, S.V.; Schroder, R. Desminopathies: Pathology and mechanisms. Acta Neuropathol. 2013, 125, 47–75. [CrossRef] [PubMed]

5. Bar, H.; Mucke, N.; Kostareva, A.; Sjoberg, G.; Aebi, U.; Herrmann, H. The biology of desmin filaments: How do mutations affect their structure, assembly, and organisation? J. Struct. Biol. 2004, 148, 137–152. [CrossRef]

6. Clemen, C.S.; Stockigt, J.R.; Strucksberg, K.H.; Chevessier, F.; Winter, L.; Schutz, J.; Bauer, R.; Thorweie, J.M.; Wenzel, D.; Schlotzer-Schrehardt, U.; et al. The toxic effect of R350P mutant desmin in striated muscle of man and mouse. Acta Neuropathol. 2015, 129, 297–315. [CrossRef]

7. Bar, H.; Mucke, N.; Kostareva, A.; Sjoberg, G.; Aebi, U.; Herrmann, H. Severe muscle disease-causing desmin mutations interfere with in vitro filament assembly at distinct stages. Proc. Natl. Acad. Sci. USA 2010, 107, 178–187. [CrossRef]

8. Vernengo, L.; Chourbagi, O.; Panuncio, A.; Lilienbaum, A.; Batonnent-Pichon, S.; Bruston, F.; Rodrigues-Lima, F.; Mesa, R.; Pizzarossa, C.; Demay, L.; et al. Desmin myopathy with severe cardiomyopathy in a Uruguayan family due to a codon deletion in a new location within the desmin 1A rod domain. Neuromuscul. Disord. 2010, 20, 179–187. [CrossRef]

9. Clemen, C.S.; Dieding, M.; Strucksberg, K.H.; Chevessier, F.; Winter, L.; Schutz, J.; Bauer, R.; Thorweie, J.M.; Wenzel, D.; Schlotzer-Schrehardt, U.; et al. The toxic effect of R350F mutant desmin in striated muscle of man and mouse. Acta Neuropathol. 2015, 129, 297–315. [CrossRef]

10. Bar, H.; Mucke, N.; Kostareva, A.; Sjoberg, G.; Aebi, U.; Herrmann, H. Severe muscle disease-causing desmin mutations interfere with in vitro filament assembly at distinct stages. Proc. Natl. Acad. Sci. USA 2005, 102, 15099–15104. [CrossRef]

11. Santhoshkumar, R.; Preethish-Kumar, V.; Polavarapu, K.; Reghunathan, D.; Chaudhari, S.; Satyamoorthy, K.; Vengalil, S.; Nashi, S.; Faruq, M.; Joshi, A.; et al. A Novel L1 Linker Mutation in DES Resulted in Total Absence of Protein. J. Mol. Neurosci. 2021, 102, 137–152. [CrossRef]

12. Riley, L.G.; Waddell, L.B.; Ghaoui, R.; Evesson, F.J.; Cummings, B.B.; Bryen, S.J.; Joshi, H.; Wang, M.X.; Brammah, S.; Kritharides, L.; et al. Recessive DES cardio/myopathy without myofibrillar aggregates: Intronic splice variant silences one allele leaving only missense L190P-desmin. Eur. J. Hum. Genet. 2019, 27, 1267–1273. [CrossRef] [PubMed]

13. Cimio, D.; Budde, H.; Haysou, R.; Jaquet, K. Genetic Restrictive Cardiomyopathy: Causes and Consequences—An Integrative Approach. Int. J. Mol. Sci. 2021, 22, 558. [CrossRef] [PubMed]

14. Cimio, D.; Fujita-Becker, S.; Mohner, D.; Smolina, N.; Budde, H.; Wies, A.; Morgenstern, L.; Gudivoka, A.; Sejersen, T.; Sjoberg, G.; et al. Infantile restrictive cardiomyopathy: cTnI-R170G/W impair the interplay of sarcomeric proteins and the integrity of thin filaments. PLoS ONE 2015, 10, e0229227. [CrossRef] [PubMed]

15. Brodehl, A.; Ferrier, R.A.; Hamilton, S.J.; Greenway, S.C.; Brundler, M.A.; Yu, W.; Gibson, W.T.; Mc Kinnon, M.L.; McGillivray, B.; Alvarez, N.; et al. Mutations in FLNC are Associated with Familial Restrictive Cardiomyopathy. Hum. Mutat. 2016, 37, 269–279. [CrossRef] [PubMed]

16. Tucker, N.R.; McLellan, M.A.; Hu, D.; Ye, J.; Parsons, V.A.; Mills, R.W.; Clauss, S.; Dolmatova, E.; Shea, M.A.; Milan, D.J.; et al. Novel Mutation in FLNC (Filamin C) Causes Familial Restrictive Cardiomyopathy. Circ. Cardiovasc. Genet. 2017, 10, e001780. [CrossRef] [PubMed]

17. Kiselev, A.; Vaz, R.; Knyazeva, A.; Khudiakov, A.; Tarnovskaya, S.; Liu, J.; Sergushichev, A.; Kazakov, S.; Frishman, D.; Smolina, N.; et al. De novo mutations in FLNC leading to early-onset restrictive cardiomyopathy and congenital myopathy. Hum. Mutat. 2018, 39, 1161–1172. [CrossRef] [PubMed]
18. Clemen, C.S.; Fischer, D.; Reimann, J.; Eichinger, L.; Muller, C.R.; Muller, H.D.; Goebel, H.H.; Schroder, R. How much mutant protein is needed to cause a protein aggregate myopathy in vivo? Lessons from an exceptional desminopathy. *Hum. Mutat.* 2009, 30, E490–E499. [CrossRef]

19. Kulikova, O.; Brodehl, A.; Kiseleva, A.; Myasnikov, R.; Meshkov, A.; Stanasiuk, C.; Gartner, A.; Divashuk, M.; Sotnikova, E.; Koretskiy, S.; et al. The Desmin (DES) Mutation p.A337P Is Associated with Left-Ventricular Non-Compaction Cardiomyopathy. *Genes* 2021, 12, 121. [CrossRef]

20. Fischer, B.; Dittmann, S.; Brodehl, A.; Unger, A.; Stallmeyer, B.; Paul, M.; Seoehm, G.; Kayser, A.; Peischard, S.; Linke, W.A.; et al. Functional characterization of novel alpha-helical rod domain desmin (DES) pathogenic variants associated with dilated cardiomyopathy, atrioventricular block and a risk for sudden cardiac death. *Int. J. Cardiol.* 2021, 329, 167–174. [CrossRef]

21. Protonotarios, A.; Brodehl, A.; Asimaki, A.; Jager, J.; Quinn, E.; Stanasiuk, C.; Ratnavadivel, S.; Futema, M.; Akhtar, M.M.; Gossios, T.D.; et al. The Novel Desmin Variant p.Leu115Ile Is Associated With a Unique Form of Biventricular Arrhythmogenic Cardiomyopathy. *Can. J. Cardiol.* 2021, 37, 857–866. [CrossRef] [PubMed]

22. Klingel, K.; Sauter, M.; Bock, C.T.; Szalay, G.; Schnorr, J.J.; Kandolf, R. Molecular pathology of inflammatory cardiomyopathy. *Med. Microbiol. Immunol.* 2004, 193, 101–107. [CrossRef] [PubMed]

23. Li, H. Minimap2: Pairwise alignment for nucleotide sequences. *Bioinformatics* 2018, 34, 3094–3100. [CrossRef]

24. Tang, A.D.; Soulette, C.M.; van Baren, M.J.; Hart, K.; Hrabeta-Robinson, E.; Wu, C.J.; Brooks, A.N. Full-length transcript characterization of SF3B1 mutation in chronic lymphocytic leukemia reveals downregulation of retained introns. *Nat. Commun.* 2020, 11, 1438. [CrossRef]

25. Brodehl, A.; Belke, D.D.; Garnett, L.; Martens, K.; Abdelfatah, N.; Rodriguez, M.; Diao, C.; Chen, Y.X.; Gordon, P.M.; Nygren, A.; et al. Transgenic mice overexpressing desmocollin-2 (DSC2) develop cardiomyopathy associated with myocardial inflammation and fibrotic remodeling. *PLoS ONE* 2017, 12, e0174019. [CrossRef]

26. Brodehl, A.; Gaertner-Rommel, A.; Klauke, B.; Grewe, S.A.; Schirmer, I.; Peterschroder, A.; Faber, L.; Vorgerd, M.; Gummert, J.; Anselmetti, D.; et al. The novel alphaB-crystallin (CRYAB) mutation p.D109G causes restrictive cardiomyopathy. *Hum. Mutat.* 2017, 38, 947–952. [CrossRef]

27. Brodehl, A.; Hedde, P.N.; Dieding, M.; Fatima, A.; Walhorn, V.; Gayda, S.; Saric, T.; Klauke, B.; Gummert, J.; Anselmetti, D.; et al. Dual color photoactivation localization microscopy of desminopathy-associated desmin mutants. *J. Biol. Chem.* 2012, 287, 16047–16057. [CrossRef]

28. Hedberg, K.K.; Chen, L.B. Absence of intermediate filaments in a human adrenal cortex carcinoma-derived cell line. *Exp. Cell Res.* 1986, 163, 509–517. [CrossRef]

29. Kubanek, M.; Schimerova, T.; Piherova, L.; Brodehl, A.; Krebsova, A.; Ratnavadivel, S.; Stanasiuk, C.; Hansikova, H.; Zeman, J.; Palecek, T.; et al. Desminopathy: Novel Desmin Variants, a New Cardiac Phenotype, and Further Evidence for Secondary Mitochondrial Dysfunction. *J. Clin. Med.* 2020, 9, 937. [CrossRef]

30. CSH Press. Recipe RIPA Lysis Buffer. *Cold Spring Harb. Protoc.* 2017. [CrossRef]

31. Brodehl, A.; Gaertner-Rommel, A.; Milting, H. Molecular insights into cardiomyopathies associated with desmin (DES) mutations. *Biophys. Res. Lett.* 2018, 10, 983–1006. [CrossRef]

32. Herrmann, H.; Cabet, E.; Chevalier, N.R.; Moosmann, J.; Schultheis, D.; Haas, J.; Schowalter, M.; Berwanger, C.; Weyerer, V.; Agaimy, A.; et al. Dual Functional States of R406W-Desmin Assembly Complexes Cause Cardiomyopathy With Severe Intercalated Disc Derangement in Humans and in Knock-In Mice. *Circulation 2020*, 142, 2155–2171. [CrossRef]

33. Arbustini, E.; Pasotti, M.; Pilotto, A.; Pellegrini, C.; Grasso, M.; Prevaliti, S.; Repetto, A.; Bellini, O.; Azan, G.; Saffino, M.; et al. Desmin accumulation restrictive cardiomyopathy and atrioventricular block associated with desmin gene defects. *Eur. J. Heart Fail.* 2006, 8, 477–483. [CrossRef]

34. Pinol-Ripoll, G.; Shatunov, A.; Cabello, A.; Larrode, P.; de la Puerta, I.; Pelegrin, J.; Ramos, F.; Olive, M.; Goldfarb, L.G. Severe infantile-onset cardiomyopathy associated with a homozygous deletion in desmin. *Neuromuscul. Disorders 2009*, 19, 418–422. [CrossRef]

35. Richards, S.; Aziz, N.; Bale, S.; Bick, D.; Das, S.; Gastier-Foster, J.; Grody, W.W.; Hedg, M.; Lyon, E.; Spector, E.; et al. Standards and guidelines for the interpretation of sequence variants: A joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. *Genet. Med.* 2015, 17, 405–424. [CrossRef]

36. Vrabie, A.; Goldfarb, L.G.; Shatunov, A.; Nagela, A.; Fritz, P.; Kaczmarek, I.; Goebel, H.H. The enlarging spectrum of desminopathies: New morphological findings, eastward geographic spread, novel exon 3 desmin mutations. *Acta Neuropathol.* 2005, 109, 411–417. [CrossRef]

37. Strach, K.; Sommer, T.; Grohe, C.; Meyer, C.; Fischer, D.; Walter, M.C.; Vorgerd, M.; Reilich, P.; Bar, H.; Reimann, J.; et al. Clinical, genetic, and cardiac magnetic resonance imaging findings in primary desminopathies. *Neuromuscul. Disorders 2008*, 18, 475–482. [CrossRef]

38. Wahbi, K.; Behin, A.; Charron, P.; Dunand, M.; Richard, P.; Meune, C.; Vicart, P.; Lafoet, P.; Stojkovic, T.; Becane, H.M.; et al. High cardiovascular morbidity and mortality in myofibrillar myopathies due to DES gene mutations: A 10-year longitudinal study. *Neuromuscul. Disorders 2012*, 22, 211–218. [CrossRef] [PubMed]

39. Brodehl, A.; Dieding, M.; Klauke, B.; Dec, E.; Madaan, S.; Huang, T.; Gargus, J.; Fatima, A.; Saric, T.; Cakar, H.; et al. The novel desmin mutant p.A120D impairs filament formation, prevents intercalated disk localization, and causes sudden cardiac death. *Circ. Cardiovasc. Genet.* 2013, 6, 615–623. [CrossRef] [PubMed]
40. Ojrzynska, N.; Bilinska, Z.T.; Franaszczyk, M.; Płoski, R.; Grzybowski, J. Restrictive cardiomyopathy due to novel desmin gene mutation. Kardiol. Pol. 2017, 75, 723. [CrossRef] [PubMed]

41. Khudiakov, A.; Kostina, D.; Zlotina, A.; Nikulina, T.; Sergushichev, A.; Gudkova, A.; Tomilin, A.; Malashicheva, A.; Kostareva, A. Generation of iPSC line from desmin-related cardiomyopathy patient carrying splice site mutation of DES gene. Stem Cell Res. 2017, 24, 77–80. [CrossRef]

42. Park, K.Y.; Dalakas, M.C.; Goebel, H.H.; Ferrans, V.J.; Semino-Mora, C.; Litvak, S.; Takeda, K.; Goldfarb, L.G. Desmin splice variants causing cardiac and skeletal myopathy. J. Med. Genet. 2000, 37, 851–857. [CrossRef]

43. Gudkova, A.; Kostareva, A.; Sjoberg, G.; Smolina, N.; Turalchuk, M.; Kuznetsova, I.; Rybakova, M.; Edstrom, L.; Shlyakhto, E.; Sejersen, T. Diagnostic challenge in desmin cardiomyopathy with transformation of clinical phenotypes. Pediatr. Cardiol. 2013, 34, 467–470. [CrossRef] [PubMed]